Category Archives: Adult Stem Cells

BrainStorm Awarded $1.5 Million Non-Dilutive Grant for 2020 by the Israel Innovation Authority – Yahoo Finance

NEW YORK and PETACH TIKVAH, Israel, April 03, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that its wholly-owned subsidiary, Brainstorm Cell Therapeutics Ltd., has been awarded a new grant of approximately $1.5 million by the Israel Innovation Authority (IIA). The grant enables Brainstorm to continue development of advanced cellular manufacturing capabilities, furthers development of MSC-derived exosomes as a novel therapeutic platform, and will ultimately enable Brainstorm to expand the therapeutic pipeline in neurodegenerative disorders.

BrainStorm's CEO Chaim Lebovits, commented, "The Israel Innovation Authority's support of our programs provides further validation for the potential of our treatments to help patients suffering from neurodegenerative disorders. The continued financial support for our research and development will further our ability to execute our strategic objectives, as we finalize our Phase 3 pivotal trial with NurOwn in ALS patients and advance our cellular technology pipeline."

The IIA has supported BrainStorm Cell Therapeutics Ltd. since 2007, providing grants totaling approximately 11.4 million USD in support of the development of NurOwn and other projects. BrainStorm will be required to pay mid-single digit royalties to the IIA based on sales of the products, up to a total of the cumulative amount of IIA grants received plus accumulated interest.

About NurOwnNurOwn (autologous MSC-NTF cells) represent a promising investigational approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. NurOwn is currently being evaluated in a Phase 3 ALS randomized placebo-controlled trial and in a Phase 2 open-label multicenter trial in Progressive MS.

Story continues

AboutBrainStorm Cell Therapeutics Inc.BrainStorm Cell Therapeutics Inc.is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwnCellular Therapeutic Technology Platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement as well as through its own patents, patent applications and proprietary know-how. Autologous MSC-NTF cells have received Orphan Drug status designation from theU.S. Food and Drug Administration(U.S.FDA) and theEuropean Medicines Agency(EMA) in ALS. BrainStorm has fully enrolled the Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six sites in theU.S., supported by a grant from theCalifornia Institute for Regenerative Medicine(CIRM CLIN2-0989). The pivotal study is intended to support a BLA filing for U.S.FDAapproval of autologous MSC-NTF cells in ALS. BrainStorm received U.S.FDAclearance to initiate a Phase 2 open-label multi-center trial of repeat intrathecal dosing of MSC-NTF cells in Progressive Multiple Sclerosis (NCT03799718) inDecember 2018and has been enrolling clinical trial participants sinceMarch 2019. For more information, visit the company'swebsite.

Safe-Harbor Statement Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorms need to raise additional capital, BrainStorms ability to continue as a going concern, regulatory approval of BrainStorms NurOwn treatment candidate, the success of BrainStorms product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorms NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorms ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorms ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTSInvestor Relations:Preetam Shah, MBA, PhDChief Financial OfficerBrainStorm Cell Therapeutics Inc.Phone: + 1.862.397.1860pshah@brainstorm-cell.comMedia:Sean LeousWestwicke/ICR PRPhone: +1.646.677.1839sean.leous@icrinc.com

Go here to read the rest:
BrainStorm Awarded $1.5 Million Non-Dilutive Grant for 2020 by the Israel Innovation Authority - Yahoo Finance

All the COVID-19 vaccines and treatments currently in clinical trials – Digital Trends

The coronavirus pandemic is a serious health risk, which is why countries around the world are racing to find vaccines and treatments. Nearly 1,000,000 cases of COVID-19 have been confirmed globally, and by the time you read this, the death toll will have surpassed 50,000.

Some potential treatments listed here were previously in clinical testing for other diseases, such as cancer, allowing the trials for COVID-19 to be fast-tracked. Many arent aimed at the coronavirus itself but instead will hopefully reduce some of the severe side effects the disease causes, like hyperinflammation and respiratory distress.

Notably, many of the proposed treatments have gone through U.S. Food and Drug Administration (FDA) approval for other uses or are currently going through that process, meaning the route to getting approved for a clinical trial to study their effects on COVID-19 patients is shorter and faster than it would be for a new drug. Some of these are being utilized under compassionate use rules, meaning they arent part of clinical trials but are being administered to COVID-19 patients in life-threatening situations.

The path from trial to treatment is long and complex. As new treatments and vaccines make their way to new phases, well update this list. For now, weve excluded those in preclinical phases.

Note: These drugs are all in the early stages of testing for efficacy against COVID-19 and taking them without supervision can have tragic consequences. An Arizona man died after reportedly taking a form of chloroquine used to clean fish tanks. Youll see a long list of potential treatments below, but many of them wont progress to wider testing or use, because theyll prove either unsafe or ineffective.

A vaccine would prevent people from getting sick, instead of treatments to alleviate the system or kill the disease once it has already infected you. Often, vaccines either use an inactive (dead) or live attenuated (less potent) version of the pathogen to build up the bodys defenses. By introducing these weakened forms to the immune system, it can start making antibodies without having to battle the virus itself. Once the body has made antibodies once, it has been trained to recognize the pathogen and can start making them again if the actual virus finds its way inside. Immunity from an inactive vaccine may not last as long, while live-attenuated types have implications for immunocompromised people. In addition, such vaccines havent proven effective for some viruses, like HIV.

Currently, there is no approved vaccine for COVID-19. Coronaviruses caused SARS in the early 2000s and MERS in 2012. The two epidemics were contained before vaccines were created, but some work was started for both. Some companies are building on that research to find a vaccine for COVID-19, which is caused by a novel coronavirus. The Coalition for Epidemic Preparedness Innovations, or CEPI, is an organization helping to accelerate vaccine development. About 35 companies and academic institutions are searching for a COVID-19 vaccine; two in phase-1 clinical trials, and over 40 in preclinical development. A few have begun testing in animals, while biotech firm Modernas attempt has started human trials.

Despite how quickly the research is being developed, there are some aspects of the process that cant be sped up, like widespread testing for side-effects and dosing. Even then, there are logistical hurdles to scaling production and distributing vaccines to affected countries. Experts are predicting it will take 18 months for a vaccine to be widely available.

Non-replicating viral vector; Adenovirus Type 5 vector (Ad5-nCoV): Adenoviruses are common viruses that can lead to bronchitis or pneumonia. Theyve been heavily studied as potential vectors for vaccines, to deliver the antigens that stimulate the production of protective antibodies. These viral vectors can also bolster the immune response in ways traditional vaccines do not.

CanSino Biologics is testing a vaccine candidate in healthy adults, the first phase of clinical testing. In 2017, the company, collaborating with the Chinese Academy of Military Medical Sciences Bioengineering Institute, developed an ebola vaccine. The potential COVID-19 vaccine, AD5-nCoV, is based on the same technology. Its a non-replicating viral vector, so it can infect cells but has been rendered incapable of multiplying. Johnson & Johnson is working on a similar type of vaccine, which will be ready for phase one trials in September.

RNA; LNP-encapsulated mRNA (mRNA 1273): The National Institute of Allergy and Infectious Diseases (NIAID) and Modernas potential vaccine builds on research into the MERS virus. Its a messenger RNA or mRNA vaccine, where a bit of the viruss genetic material gets injected into your muscle. The role of mRNA is to carry genetic information from DNA needed to make proteins. The RNA is packaged in lipid nanoparticles (LNPs), to help effectively deliver it. The mRNA would deliver instructions to cells on how to make proteins to fight the virus. No RNA vaccines have even been approved for human use, but this effort is one of several backed by CEPI.

Monoclonal antibodies (mAb) are used in treatments for cancer and ebola. Made in a laboratory, these molecules work as substitute antibodies, according to the Mayo Clinic, boosting or mimicking the bodys immune system to attack the virus. They can do so in a variety of ways, including flagging cells for destruction and binding to different types of cells. The majority of those being researched for COVID-19 are in the pre-clinical phase, but several are in clinical trials right now.

Actemra (tocilizumab): Small proteins known as cytokines are part of the bodys immune response, released when theres an infection. Inflammation is a side effect, as blood and other fluids flow to the source of infection. A cytokine storm is when an abundance of the proteins cause hyperinflammation, which can lead to serious complications and death. It has been reported in SARS and MERS patients and could be causing some of the more severe symptoms in some people with COVID-19. Interleukins are one group of cytokines. Actemra is a rheumatoid arthritis drug that blocks interleukin-6 (IL-6) to keep it from attacking healthy tissue when the immune system overreacts. It helped several critical COVID-19 patients recover, but a controlled clinical study needs to be performed, according to The Wall Street Journal.

Avastin (bevacizumab): In healthy adults, vascular endothelial growth factor (VEGF) promotes the formation of new blood vessels and is important for healing wounds. Some COVID-19 patients have been shown to have elevated levels of VEGF, possibly due to hypoxia (low blood oxygen) and inflammation. Avastin is a VEGF blocker and has been used to treat several types of cancer for over 15 years. A clinical trial at the Qilu Hospital of Shandong University in Jinan, China will assess its effectiveness at treating shortness of breath.

Gimsilumab: Gimsilumab is a monoclonal antibody that targets a pro-inflammatory cytokine known as a granulocyte-macrophage colony-stimulating factor (GM-CSF). Its presence can elevate the expression of pro-inflammatory cytokines, causing a kind of feedback loop that increases inflammation. GM-CSF has been found in elevated levels of COVID-19 patients admitted to the ICU, according to pharmaceutical company Roivant. It wants to test Gimsilumab as a treatment for acute respiratory distress syndrome (ARDS). The condition is caused by fluid build-up in the lungs air sacs and the breakdown of surfactant, so that lungs cant fully inflate. Targeting GM-CSF represents a promising strategy for curbing lung damage while allowing time for the virus to clear, Dr. Elizabeth Volkmann, founder and co-director of the UCLA Connective Tissue Disease-Related Interstitial Lung Disease Program, said in Roviants press release.

Kevzara (sarilumab): Like Actemra, Kevzara is a rheumatoid arthritis drug that blocks IL-6. Dr. Naimish Patel told The Wall Street Journal why blocking that cytokine could help COVID-19 patients recover: Even though the virus is diminishing, its sending signals to the immune system to keep attacking. Hes head of global development for immunology and inflammation for Sanofi, which makes Kevzara, along with Regeneron.

Leronlimab (PRO 140): CCR5 is a protein on the surface of white blood cells that plays an important role in the way HIV develops in the human body. Leronlimab is a monoclonal antibody being studied as a potential treatment for HIV. It binds to the CCR5 receptor, which inhibits the release of inflammatory cytokines. Biotechnology company CytoDyn modified its clinical trial to evaluate Leronlimabs effect on severe cases of COVID-19.

PD-1 blocking antibody: There are two types of tolerance in your immune system. Central tolerance is the main way it distinguishes your own cells from outside threats, while peripheral tolerance keeps the body from over-reacting when it encounters allergens or microbes. Usually, the protein programmed cell death-1 (PD-1) helps limit T cell activity during infection to reduce inflammation. But if PD-1 binds to another protein, PD-L1, it prevents T cells from attacking cancerous cells. Monoclonal antibodies that block PD-1 are known as immune checkpoints inhibitors (ICIs). Theyve shown success in treating various types of tumors by preventing PD-1 from binding with PD-L1, freeing T cells to target the tumor. Thymosin, meanwhile, targets PD-L1. A clinical trial at Southeast University in China will study the efficacy of PD-1 and thymosin in COVID-19 patients with severe pneumonia caused by lymphocytopenia (low levels of lymphocytes, including T cells).

Sylvant (siltuximab): Another monoclonal antibody that blocks the action of IL-6, siltuximab is approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to treat multicentric Castleman disease (MCD). This rare lymph node disease acts similarly to lymphoma, causing an overgrowth of cells. Doctors at Papa Giovanni XXIII Hospital in Italy will observe its effects on patients with COVID-19, in the hopes it will reduce inflammation in those with severe respiratory disorders.

TJM2 (TJ003234): TJM2, like Gimsilumab, is a monoclonal antibody that targets pro-inflammatory cytokine GM-CSF. In November 2019, the FDA approved it for clinical trials to treat rheumatoid arthritis. I-Mab Biopharma, which makes TJM2, is a U.S.- and China-based biopharmaceutical company. It will now explore the mAbs effectiveness in fighting cytokine storming in patients with serious reactions to COVID-19.

There are a variety of antiviral drugs for diseases like hepatitis, the flu, and herpes many of which could potentially be repurposed to fight coronavirus. They work in different ways to stop the replication of viruses. For example, some flu antivirals are neuraminidase inhibitors. Neuraminidases are enzymes that cut acids and proteins on the surface of virus envelopes, releasing the replicated virus to infect new cells. Neuraminidase inhibitors can help reduce the amount of new viruses that are released inside the human body. The hope is that some of these antivirals will also stop the replication of COVID-19 once a patient has contracted it, lessening the duration or severity of the disease.

Arbidol (umifenovir): This broad-spectrum antiviral blocks virus entry into healthy cells by inhibiting membrane fusion. Its not currently approved by either the EMA or FDA, though it is available in Russia and China. A study at the Guangzhou 8th Peoples Hospital in China will observe its effect on patients with COVID-19. Though people are selling Arbidol on eBay in the U.K., the Medicines and Healthcare Regulatory Agency told The New Statesman, Not only are they breaking the law, they are acting with total disregard of your health.

ASC09: HIV requires protease enzymes to reproduce. Protease inhibitors prevent newly replicated viruses from maturing and invading healthy white blood cells. To see if the same disruption works on COVID-19, China-based biotechnology company Ascletis Pharma will test ASC09 in clinical trials.

Azvudine: Azvudine is a nucleoside reverse transcriptase inhibitor (NRTI). HIV uses the enzyme reverse transcriptase in reverse transcription, converting RNA into DNA. Inhibitors block the enzyme, preventing the virus from replicating. The clinical trial for Azvudines efficacy against COVID-19 will take place at the Peoples Hospital in Guangshan County, China.

Favilavir/Favipiravir/T-705/Avigan: Favipiravir is a broad-spectrum antiviral thats been utilized in Japan to treat influenza. Inside cells, it mimics the organic compound purine and eventually becomes included in the viruss RNA strand as it grows. Exactly how Favipiravir inhibits viral RNA synthesis once its incorporated is unclear, but there is some indication it could be used in COVID-19 patients as well. In clinical trials in China, patients who received the medication tested negative for the virus after a median of four days; those who didnt receive it took 11 days to test negative, according to The Guardian.

Ganovo (danoprevir): Ascletis Pharma developed Ganovo as a direct-acting antiviral agent (DAA) to treat hepatitis C. The efficacy of DAAs in general has been called a monumental advance over previous hepatitis C therapies. Ganovo inhibits the viruss protease, which is necessary for its replication. The effectiveness of Ganovo, in combination with another protease inhibitor (ritonavir), will be tested at Chinas Ninth Hospital of Nanchang.

Kaletra/Aluvia (lopinavir/ritonavir): Kaletra is a combination of protease inhibitors ritonavir and lopinavir, used to treat HIV. Earlier this year, The New England Journal of Medicine published the results of a study of 199 patients with severe COVID-19 patients at Jin YinTan Hospital in China. Those that received the lopinavir-ritonavir treatment saw no difference in the mortality rate. Future trials in patients with severe illness may help to confirm or exclude the possibility of a treatment benefit, according to the authors of the study.

Prezcobix (darunavir): Like ASC09, Prezcobix is a protease inhibitor, used to treat HIV, in conjunction with a pharmacokinetic enhancer. Cobicistat is one such drug, which slows the breakdown of Prezcobix, allowing it to stay in the body for longer and at a higher concentration. Johnson & Johnson sent Prezcobix to Chinese health authorities in January to gauge its effectiveness in treating COVID-19. The companys chief scientific officer, Paul Stoffels, told The Wall Street Journal that studying the drugs effects in ill patients could help researchers find a treatment that works.

Remdesivir: This drug has gotten more press than many of the other potential treatments. Its a broad-spectrum antiviral, and has been studied as a treatment for Middle East respiratory syndrome (MERS), a respiratory illness that is caused by the same family of viruses as COVID-19. Gilead, the company that makes Remdesivir, hoped the drug would work against Ebola, but it wasnt nearly as effective as two other drugs at preventing death from the disease. Some experts are hopeful that it will have more luck with COVID-19, and there are several clinical trials underway.

Truvada (emtricitabine and tenofovir): You may have seen commercials for this drug for whats known as PrEP (pre-exposure prophylaxis). When taken properly, it can reduce the risk of HIV infection. Truvada is a combination of two antiretroviral medications: emtricitabine and tenofovir. Both prevent HIV from replicating, and while they work in different ways, each blocks the reverse transcriptase enzyme needed for reproduction. The Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital are conducting the clinical trial for Truvada against COVID-19.

Xofluza (baloxavir marboxil): Endonuclease is an enzyme that initiates flu virus replication. Polymerase acidic endonuclease inhibitors, like Xofluza, interfere with that replication. Xofluza received FDA approval in 2018 to treat the flu, and now the First Hospital Affiliated of Zhejiang Universitys Medical School wants to research the drug as a treatment option for COVID-19 patients with pneumonia.

Cellular therapy replaces or repairs damaged cells or tissues and is used in a range of diseases. Many types of cells have been studied for this purpose, including stem, progenitor, and primary cells. Cell therapy is being used and researched for everything from inflammatory bowel disease to cancer. CAR T-cell, for example, is a therapy in which doctors modify a patients T cells to identify and go after cancer cells.

Mesenchymal stem cells: Stem cells can self-renew through cell division and can also differentiate into different types of cells, like bone cells or liver cells. Mesenchymal stem cells (MSCs) are adult stem cells and can be taken from either humans or animals. Pneumonitis, or the inflammation of the walls in the air sacs of the lungs, is one potential side-effect of COVID-19. There has been some research on using MSCs to treat lung damage caused by radiation for cancer treatment. Chinas Institute of Basic Medicine is conducting clinical trials to see the cell therapys effect on COVID-19 patients with pneumonitis.

MultiStem: Biotech company Athersys created MultiStem, a stem cell product made from multipotent adult progenitor cells (MAPCs) derived from bone marrow. MPACs can self-renew and differentiate into several cell types. Acute respiratory distress syndrome (ARDS) is similar to pneumonia; it makes it difficult for the lungs to fully inflate and can lead to serious complications and death. MultiStem already underwent an early-stage clinical trial for treating ARDS, and the results showed the patients had lower mortality rates and were off ventilators more quickly than those who didnt receive the treatment. The company is working with the FDA to fast-track a clinical trial testing for COVID-19, according to WKSU.

RNA therapies are a fairly recent development and are being studied to treat several diseases, including macular degeneration and Zika. The therapies work in a few different ways, either by targeting nucleic acids (DNA or RNA), targeting proteins, or encoding proteins. A therapy might prevent messenger RNA from being translated into protein or it might encode a normal version of a protein instead of a mutated one. Right now, the potential RNA therapies for COVID-19 are all in preclinical phases.

There are a number of other treatments scientists are researching to see if they can help alleviate some of the severe symptoms of COVID-19. They dont necessarily fit into the categories above.

APN01: Scientists have found that during infection, COVID-19s viral trimeric spike protein binds to human receptor angiotensin-converting enzyme 2 (ACE2). One study showed that deactivating ACE2 caused severe lung injury in mice infected with a strain of avian influenza while administering recombinant human ACE2 was effective at lessening the damage. APN01 is a recombinant human angiotensin-converting enzyme 2 (rhACE2) created by Aperion Biologics to treat acute lung injury (ALI), acute respiratory distress syndrome (ARDS), and pulmonary arterial hypertension (PAH). The company began a clinical trial with APN01 on COVID-19 patients in February. A similar trial is underway at the First Affiliated Hospital of Guangzhou Medical University.

Chloroquine/Hydroxychloroquine: These two antimalarial drugs have been getting a lot of attention, though their efficacy as a treatment for COVID-19 is still unknown. Malaria is caused by a parasite, while COVID-19 is caused by a virus. The reason some researchers are looking at these drugs as potential coronavirus treatments is that chloroquine and other drugs were able to block coronaviruses from infecting cells in laboratory testing. These drugs were researched as possible treatments for MERS during the 2012 outbreak. The mechanism by which these malarial drugs would work against COVID-19 is uncertain, but one hypothesis is they change cells surface acidity, so the virus cant infect them. Or chloroquines might activate the immune system. Chloroquine and hydroxychloroquine have not been appropriately evaluated in controlled studies, not to mention that they have numerous and, in some cases, very deadly side effects, Katherine Seley-Radtke, professor of chemistry and biochemistry at the University of Maryland, wrote at The Conversation. There are a few clinical trials underway looking into their efficacy.

Gilenya (fingolimod): Multiple sclerosis causes the bodys own immune system to attacknerves insulating layer, or myelin. The presence of pro-inflammatory white blood cells in the central nervous system can also damage the myelin sheath. A sphingosine 1-phosphate receptor modulator is believed to keep certain white blood cells (lymphocytes) from leaving the lymph nodes and crossing the blood-brain barrier, where they would further damage nerve cells. Pneumonia is an acute inflammatory response that develops in some people with COVID-19, and the First Affiliated Hospital of Fujian Medical University wants to test this MS drugs effectiveness on reducing its severity.

Jakafi/Jakavi (ruxolitinib): Myelofibrosis is a somewhat rare blood cancer in which fibrous scar tissue replaces spongy bone marrow. Many patients with this and a couple of other types of blood cancer have an acquired mutation in the Janus Kinase 2 gene. It causes bone marrow to produce too many abnormal blood cells. Janus kinase inhibitors, or JAK inhibitors, block the function of these enzymes. Because of their role in cytokine production, JAK inhibitors are also used to treat inflammatory diseases, including rheumatoid arthritis. (Cytokines are a normal part of the bodys response to infection, but an overabundance can lead to hyperinflammation.) Patients with severe reactions to COVID-19 could have an excess of cytokines causing lung inflammation. A clinical trial at Tongji Medical College of Huazhong University of Science and Technology will study the effect of Jakafi and mesenchymal stem cells on COVID-19 patients with pneumonia.

Losartan: Angiotensin is a peptide hormone that constricts blood vessels and raises blood pressure. Angiotensin II receptor antagonists or blockers are prescribed for hypertension because they block the hormone. Losartan is one such drug, and the University of Minnesota is conducting clinical trials to see its effect on lung inflammation in COVID-19 patients.

Methylprednisolone/corticosteroids: Methylprednisolone is a synthetic corticosteroid, which mimics how the bodys hormones work to reduce inflammation. Corticosteroids are used to treat a plethora of conditions, from asthma to lupus to arthritis. Though they were used during severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks, the World Health Organization doesnt currently advise the use of corticosteroids for COVID-19, according to a February article from The Lancet. Clinical trials for glucocorticoid therapy are going forward at Peking Union Medical College Hospital and Tongji Hospital.

Novaferon: Interferons are cytokine mediators that alert the immune system when theres a viral infection. Lab-made interferons are used to treat several diseases, including hepatitis B. Exactly how interferons affect the virus is unclear, but its thought to interfere with its life cycle, while also boosting cell-mediated immunity. Novaferon is one man-made interferon used to treat hepatitis B, and the First Affiliated Hospital of Zhejiang University Medical School will study whether its effective against COVID-19.

Rebif (interferon beta-1a): Interferon beta-1a is an interferon used to treat multiple sclerosis. Exactly how Rebif, an interferon made by Merck KGaA, works in MS patients isnt known, but it does lessen inflammation and reduce the bodys immune response that damages the myelin sheath. The French Institut National de la Sant et de la Recherche Mdicale (INSERM) will use Rebif in a clinical trial, to see if it similarly reduces inflammation in COVID-19 patients.

Washed microbiota transplantation: Some people who take antibiotics end up wiping out their colon of the healthy bacteria that help stave off clostridium difficile (C. difficile), which can lead to a serious infection. Fecal microbiota transplantation (FMT) reintroduces healthy bacteria via a donors stool, transferred by colonoscopy or another procedure. The washed microbiota process is a way of purifying the sample beforehand. A clinical trial at the Second Affiliated Hospital of Nanjing Medical University is doing a clinical trial on the procedure to examine its effect on COVID-19 patients with antibiotic-associated diarrhea.

Read the original here:
All the COVID-19 vaccines and treatments currently in clinical trials - Digital Trends

Post-Remission Therapy For AML: Allogeneic Stem-Cell Transplant – SurvivorNet

When treating Acute Myeloid Leukemia, its important to recognize the distinction between remission and cure. When their Acute Myeloid Leukemia is in remission and everything looks good, a lot of patients say, Thanks. Im done, right? saysDr. Richard Stone, director of the Adult Acute Leukemia Program at Dana-Farber Cancer Institute in Boston.

Instead, when a patient enters remission, it signals that theyre ready for the final phase of treatment. Post-treatment therapy offers the chance of a cure. It also reduces the risk of a recurrence, which can be caused by residual leukemia cells that may have remained in the blood after treatment.

Oh no. Sorry, Dr. Ston tells patients who assume remission means their treatment is over. We need to give you some more therapy to kill off those residual, undetectable leukemia cells, so we can go from remission to cure, he explains.

And thats really what were talking about in AML therapy today. We want to get you into remission and we have a great chance of doing that in most patients. And we want to cure you with post-remission therapy.

And autologous stem cell transplant involves taking the patients own stem cells, giving them high doses of chemotherapy, and then giving those cells back. We dont do that very much, says Dr. Stone.

The other big choice isallogeneic stem cell transplant, often called bone marrow transplant.And thats where we give you, the patient, chemotherapy to put your immune system to sleep, says Dr. Stone, adding that sometimes radiation is included in the pre-transplant treatment plan for the same purpose.And then we give you cells from another individual.

We give you those (donor) cells to replenish your bone-marrow compartment, where we expect those donated cells tokill off the residual undetected leukemic cells. The result is called Graft vs. Leukemia effect, which means the donor cells have killed off any residual leukemia cells. Thats why stem-cell transplantation is a very effectiveanti-leukemic therapy, Dr. Stone explains.

Why dont we do it in everybody? he asks. Because its pretty dangerous and we dont do unless we really think thats the only way we have to cure you.

Learn more about SurvivorNet's rigorous medical review process.

Dr. Richard Stone is Director of the Adult Acute Leukemia Program at DFCI. Read More

When treating Acute Myeloid Leukemia, its important to recognize the distinction between remission and cure. When their Acute Myeloid Leukemia is in remission and everything looks good, a lot of patients say, Thanks. Im done, right? saysDr. Richard Stone, director of the Adult Acute Leukemia Program at Dana-Farber Cancer Institute in Boston.

Instead, when a patient enters remission, it signals that theyre ready for the final phase of treatment. Post-treatment therapy offers the chance of a cure. It also reduces the risk of a recurrence, which can be caused by residual leukemia cells that may have remained in the blood after treatment.

And thats really what were talking about in AML therapy today. We want to get you into remission and we have a great chance of doing that in most patients. And we want to cure you with post-remission therapy.

And autologous stem cell transplant involves taking the patients own stem cells, giving them high doses of chemotherapy, and then giving those cells back. We dont do that very much, says Dr. Stone.

The other big choice isallogeneic stem cell transplant, often called bone marrow transplant.And thats where we give you, the patient, chemotherapy to put your immune system to sleep, says Dr. Stone, adding that sometimes radiation is included in the pre-transplant treatment plan for the same purpose.And then we give you cells from another individual.

We give you those (donor) cells to replenish your bone-marrow compartment, where we expect those donated cells tokill off the residual undetected leukemic cells. The result is called Graft vs. Leukemia effect, which means the donor cells have killed off any residual leukemia cells. Thats why stem-cell transplantation is a very effectiveanti-leukemic therapy, Dr. Stone explains.

Why dont we do it in everybody? he asks. Because its pretty dangerous and we dont do unless we really think thats the only way we have to cure you.

Learn more about SurvivorNet's rigorous medical review process.

Dr. Richard Stone is Director of the Adult Acute Leukemia Program at DFCI. Read More

See original here:
Post-Remission Therapy For AML: Allogeneic Stem-Cell Transplant - SurvivorNet

Intermittent fasting might boost the creation of new neurons in a key brain structure – PsyPost

The connection between what and when we eat, and the structure and functionality of the brain, is one of the most complex relationships in modern medicine. But understanding this relationship will lead to fewer diseases, healthier minds, and longer lives. One regimen in particular, Intermittent Fasting (IF), has been shown to bolster the creation of new neurons (a process known as neurogenesis) in the hippocampus, a part of the brain involved in short and long term memory (and also one of the first casualties of Alzheimers disease).

Intermittent Fasting is a type of diet in which one regularly forgoes food for a certain period of time, usually somewhere between 14 and 18 hours. While its been known that IF increases the rate of hippocampal neurogenesis, the precise nature of the relationship is still poorly understood. To remedy this, researchers from the Universities of Singapore and Sungkyunkwan in Korea took a closer look at how IF affected change in the hippocampi of mice over a three month period in new research published in Brain and Behavior.

The mice were randomly assigned to four dietary groups: a control with no restrictions, and 12-hour, 16-hour and 24-hour fasted diets. The 12- and 16-hour groups fasted from either 3PM or 7PM to 7AM the next day, while the 24-hour group fasted every other day. Despite the varied schedules, all the mice ended up eating roughly the same number of calories.

As expected, all three dietary groups showed increased levels of neurogenesis in the hippocampus, with the most significant change in 16-hour mice. To better understand what was going on, the authors used a procedure called an immunoblot analysis, which can accurately detect certain proteins in a given tissue sample.

The analysis revealed an increased activation of the Notch signaling pathway, a type of cell-to-cell communication thats important to cell differentiation, the process by which immature cells, like stem cells, take on a permanent form and function. In humans, Notch signaling is related to hippocampal neuroplasticity, the brains ability to create new connections, allowing us to learn and form new memories.

We still have a long way to go before fully understanding how our diets affect the structure and function of our brains. Studies like this one can help us make better-informed decisions for leading healthier and longer lives, while retaining our memories and maintaining cognitive faculties.

The study, Intermittent fasting increases adult hippocampal neurogenesis, was authored by SangHa Baik, Vismitha Rajeev, David YangWei Fann, DongGyu Jo, and Thiruma V. Arumugam.

Read the original here:
Intermittent fasting might boost the creation of new neurons in a key brain structure - PsyPost

4 relationship problems that can be linked back to early childhood – Big Think

Fear of abandonment can stem from childhood loss or childhood maltreatment.

Photo by Koldunova Anna on Shutterstock

"Powerful experiences can alter the functioning of an adult brain, but with children, traumatic events may change the entire framework of their brain." - Dr. Bruce Perry, Senior Fellow of the Child Trauma Academy.

Fear of abandonment can stem from childhood loss - the death of a parent or loved one - but it can also stem from maltreatment during childhood. Maltreatment or neglect as a child can be difficult to pinpoint, especially if that mistreatment isn't physical but more of an emotional nature.

Brain development, according to this Child Welfare Information Gateway study, is actually the process of creating, strengthening and discarding connections among the neurons we're born with.

These connections are called synapses and they organize the brain by forming neural pathways that connect various parts of the brain governing everything we do.

The growth of each region of the brain depends largely on receiving stimulation for that area - think of it as a muscle that needs to be exercised in order to grow strong and be useful. Leaving that muscle unattended, not giving it movement and strength, will eventually lead it to atrophy, making it a deterrent for your entire body to function properly.

This is how maltreatment works. To remedy this issue in your relationship, work on exercising that "attachment muscle", allowing yourself to become more vulnerable and open with your partner.

An inability to commit to the relationship can be really difficult to overcome.

Photo by Motortion Films on Shutterstock

This 2016 study by Winston and Chicot offers proof to the theory that parental inconsistency and lack of love can lead to long-term mental health problems as well as to reduced overall potential and happiness later in life.

The human brain is made of over 100 billion brain cells that each connect to over 7000 other brain cells - it's an extremely complex system. And yet - by the age of 3, a child's brain has reached more than 90% of its adult size.

The experiences that a baby has within the first three years of life lay the ground for how their brain is wired well into adulthood. While it's possible for us to "re-learn" things as adults and change the framework of our brains this way - there is much importance laid on the connection and relationship that an infant has with their caregiver.

Longitudinal studies have proven that a child's inability to form and maintain healthy relationships throughout life may be significantly impaired by having an insecure attachment to a primary caregiver during their early development years.

To address this common relationship problem, consider how you view attachment, dedication and loyalty in relationships - there is a good chance you are already very committed to your partner but simply fear the "label" of being so invested in a relationship.

Entitlement can be an unrealistic, unmerited and inappropriate sense of how you should be treated and what you deserve.

Image by Artur Szczybylo on Shutterstock

Entitlement, defined as an unrealistic, unmerited or inappropriate expectation of favorable living conditions and treatment by others, can also stem back to the experiences we have during childhood. To remedy this issue in a relationship can be quite difficult, as entitlement is an inherently selfish quality.

According to Better Help, there are two main reasons why people act entitled in relationships - they are either overcompensating for never getting what they want or are so used to getting what they want that they can't even entertain the possibility of not getting what they want.

Overcompensating for past wrongs - an example being a child who grows up lacking the toys, games, and clothes owned by their peers may grow up to believe they are entitled to what they missed out on.

A habit of getting what they want all the time - an example being a child who was given whatever they asked for without reason which can lead them to believe they should always get what they ask for even if it's not realistic.

Childhood emotional neglect is a deep and long lasting wound that can impact all future relationships.

Photo by rawf8 on Shutterstock

Childhood emotional neglect is a deep and long-lasting would that isn't always easily detectable. In fact, many times, these feelings of worthlessness and defectiveness that children feel aren't imposed by parents who mean harm to their child.

According to Good Therapy, there are four different kinds of parenting styles that can lead to your child feeling worthless or defective.

Authoritarian parents: they want their children to follow the rules but have very little time or inclination to listen to their child's feelings or needs.

Permissive parents: they have a very laid back attitude about child-rearing, but they may be too laid back - which may let children do what they wish and "fend for themselves." This can lead to children feeling as though they "aren't worthy of their parent's time" and in the future, they may feel unworthy of their romantic partner's time as well.

Narcissistic parents: they feel as though the world (and their children) revolve around them, placing their own needs and desires above those of their children. Adults who were raised by narcissistic parents may always allow their partner's needs and wants to overshadow their own, feeling as though they are not worthy of having their own needs met.

Addressing issues of self-worth often involve therapy, self-help programs and a lot of time to heal and retrain your brain in how you view yourself.

"Our brains are sculpted by our early experiences. Maltreatment is a chisel that shapes a brain to contend with strife but at the cost of deep, enduring wounds." - Teicher, 2000.

From Your Site Articles

Related Articles Around the Web

Continued here:
4 relationship problems that can be linked back to early childhood - Big Think

Scientists Have ‘Reset’ The Cellular Age Of Cells Taken From A 114-Year-Old Woman – IFLScience

For the first time, scientists have reprogrammed cells from a 114-year-old woman into induced pluripotent stem cells (iPS cells), a move which they describe as a significant step toward understanding"the underlying mechanisms of extreme longevity and disease resistance."

iPS cells are adult cells that have been genetically reprogrammed into an embryonic stem cell-like state and are able to give rise to any of the specialized cell types of the body, whether its neurons, blood cells, or heart cells.

Until this new project, researchers werent even certain whether they could create viable iPS cellsfrom someone so elderly, let alone a supercentenarian. Now they have shown it's possible to effectively make these aged cells resemble young pluripotent cells, the researchers believe they might have made a step towards the reversal of cellular aging.

"We set out to answer a big question: Can you reprogram cells this old?" Evan Snyder, stem cell researcher at Sanford Burnham Prebys Medical Discovery Institute in California, said in a statement.

"Now we have shown it can be done, and we have a valuable tool for finding the genes and other factors that slow down the aging process."

Reporting in the journal Biochemical and Biophysical Research Communications, researchers harnessed iPS cells from the blood cells of a 114-year-old woman, a healthy 43-year-old person, and an 8-year-old child with a rare genetic condition characterized by the rapid aging in childhood. These iPS cells were then turned into mesenchymal stem cells, cells that help maintain and repair the body's structural tissues differentiating into bone, cartilage, muscle, or fat cells.

Remarkably, the cells produced from the supercentenarian transformed just as easily as the others. They also noted the supercentenarian-derived stem cells appeared to have reset their telomeres.

Telomeresarethe protective caps on the end of a chromosome. Since they shorten each time a cell copies itself, they also get shorter as we age and eventually stop functioning properly. Thispersistent shortening allows researchers to use telomeres as a kind of aging clock in every cell.Interestingly, the stem cells from the supercentenarian showed no indication of this aging. They had effectively reset the clock on the cells from114 years to zero.

To dive deeper into this discovery, the researchers hope to compare body cells derived from the healthy iPSCs and supercentenarian iPSCs. The researchers could also start to use the supercentenarian cells to understand why certain people have such long lives compared to others.

Why do supercentenarians age so slowly? We are now set to answer that question in a way no one has been able to before, said Snyder.

Link:
Scientists Have 'Reset' The Cellular Age Of Cells Taken From A 114-Year-Old Woman - IFLScience

The Answer to the Coronavirus Is More Abortion? – Townhall

The Abortion Lobby has taken political operative Rahm Emanuels infamous advice to heart: You never want a serious crisis to go to waste. And what I mean by that is an opportunity to do things that you think you could not do before. In some unprecedented power grabs, abortion advocates are using the crisis of the coronavirus to infiltrate the medical profession and taxpayer resources with political overreach that attempts to make the business of abortion the one thing in America that doesnt come to a halt.

Overreach #1: Pretending that abortion is healthcare, an essential service. The abortion industry has argued that in light of the need to prioritize essential and nonessential care for Covid-19 sufferers and the public at large, abortion must be considered a vital procedure.

The American College of Obstetricians and Gynecologists made a public statement calling for uninterrupted abortions as an essential component of comprehensive health care. It was a view that the abortionists lobby, the National Abortion Federation, shared in spades, saying, During this public health crisis, pregnancy care, including abortion care, remains an essential health service Abortion is provided for almost one in five pregnancies in the United States, as part of the continuum of pregnancy care. A continuum that ends in death, if the abolitionist gets a fee.

Some states initially determined that abortion needed to be prioritized, such as in Massachusetts and New York, but that is changing in some locations.

In Ohio, Attorney General Dave Yost ordered abortion vendors to stop the abortion surgeries though in the same timeframe The Womens Med Center of Dayton and Planned Parenthood of Greater Ohio told the Dayton Daily News that they will remain open.

Meera Shah, chief medical officer for Planned Parenthood in the New York City suburbs of Long Island, Westchester, and Rockland told Buzzfeed that they wouldnt close, saying, Pregnancy-related care, especially abortion care, is essential and life-affirming.

Seriously? Far from an essential service, abortion is not a treatment curing pregnancy. Prioritizing ending life in the name of a life-ending virus is heartless in the extreme.

Overreach #2:Trying to coerce more healthcare workers to end life. ACOG advises, Community-based and hospital-based clinicians should consider collaboration to ensure abortion access is not compromised during this time."

Talking with the Huffington Post, the Very Rev. Katherine Hancock Ragsdale, president of the National Abortion Federation, echoed the desire to address what the abortion-supporting think tank the Guttmacher Institute calls a shortage of clinicians who can provide sexual and reproductive health services.

One or two people unable to show up can make the difference between a clinic being able to function or not, she said, arguing for more physicians to join in a business that ends life to replace any abortionists who cant work.

This pitch comes as abortionist shortages exist nationwide not because of a virus, but because real healthcare professionals dont want to kill preborn babies through abortion.

Overreach #3: Urging Americans to stock up on birth control so that when the quarantine is over, we dont welcome new life. Planned Parenthood lectures Americans about not using their alone time to result in a Coronavirus Baby Boom. Dont worry, says the Associated Press, Family planning providers around the country are taking steps to help prevent a boom in pregnancies due to coronavirus self-isolation.

We remain committed to delivering compassionate, non-judgmental reproductive and sexual health care to all who need it while we take proactive measures to stay as far ahead of COVID-19 as possible," said Meagan Gallagher, chief executive officer of Planned Parenthood of Northern New England, to the AP.

But its pretty judgmental to lecture people that new life will be unwelcome.

Overreach #4:Insinuating that without human organs from aborted infants, there will be a delay in treatment for coronavirus sufferers.

This kind of heartlessness strikes at the fear that treatment could be delayed without opening up another profit center for abortion vendors the sale of human remains, the broken bodies of aborted infants. The Washington Post, in a recent report, noted the complaints of a researcher who wanted infant remains, despite the fact that many cell lines are available for use and that successful treatments have come from ADULT stem cells, not aborted fetal cells.

The Charlotte Lozier Institute notes that fetal cells have not been used to create vaccines, such as needed today for Covid-19. Consider that the historical fact is that fresh aborted fetal tissue has never been used in vaccine production. The original Salk and Sabin polio vaccines used monkey tissue to grow virus. While there are a couple of historical cell lines that were grown from abortions in the 1960s, kept in cell culture, and used for some vaccines, even these cell lines are obsolete and no longer used for most vaccines today.

Overreach #5: Pressuring the FDAto reduce the medical standards for distributing life-ending abortion drugs, so that they can be handed out in ways known to harm women. Abortion drugs given to women later in pregnancy or experiencing an ectopic pregnancy have resulted in womens deaths, leading to regulations from the FDA that include a physical examination for womens safety.

But that hasnt stopped abortion vendors from trying to sell the pills on-line or pushing for reduced safety standards so they can make a buck faster.

Leading abortionist Dr. Daniel Grossman called telemedicine the perfect solution for women looking to terminate early pregnancies, according to Mother Jones unless you care about complications to hurting women, that is.

Overreach #6: Attempting to infiltrate the Covid-19 aid package with healthcare dollars that could be used for abortions. Faced with a nation fearing disastrous consequences from the coronavirus, what did abortion extremists in the U.S. House of Representatives do? Add healthcare dollars that could be used to pay for abortions. But President Trump and pro-life allies were able to win Hyde Amendment protections to keep the package focused on disaster relief not taxpayer funded abortion.

Overreach #7:Pretending that the pro-life policies of the Trump administration have harmed current life-saving efforts. The Guttmacher Institute, in detailing their complaints of the Covid-19 response, listed a number of policies, from limiting taxpayer funds from paying for abortions around the world (the Mexico City Policy) to changes in the Title X program that wont allow abortion vendors to market their services to women looking for family planning services. What do those things have to do with Covid-19? Nothing, but that doesnt stop the complaints.

In a recent fundraising appeal, Planned Parenthood Action Fund (PPAF) asked for donation as they told supporters, We are working tirelessly to ensure that everyone gets the care they need, and to advocate for policies that protect and expand our health and rights. A strange appeal at a time in which the life-saving care that people should be donating to for their actual health is taking place everywhere but in abortion facilities. But in a business marked by crass opportunism, what more do you expect.

Go here to read the rest:
The Answer to the Coronavirus Is More Abortion? - Townhall

Mesoblast limited (NASDAQ:MESO) Given Consensus Rating of Buy by Brokerages – Redmond Register

Mesoblast limited (NASDAQ:MESO) has received an average rating of Buy from the nine brokerages that are presently covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $13.83.

Several brokerages recently commented on MESO. Zacks Investment Research downgraded Mesoblast from a buy rating to a hold rating in a report on Tuesday, March 3rd. Maxim Group reiterated a buy rating and set a $16.00 target price on shares of Mesoblast in a report on Friday, February 28th. HC Wainwright reiterated a buy rating and set a $14.00 target price on shares of Mesoblast in a report on Thursday, February 6th. TheStreet upgraded Mesoblast from a d rating to a c- rating in a report on Monday, December 2nd. Finally, Dawson James began coverage on Mesoblast in a report on Thursday, December 19th. They set a buy rating and a $14.00 target price on the stock.

Several large investors have recently made changes to their positions in MESO. M&G Investment Management Ltd. purchased a new stake in shares of Mesoblast during the 4th quarter valued at about $10,440,000. Tobias Financial Advisors Inc. purchased a new stake in Mesoblast during the 4th quarter worth approximately $191,000. Penbrook Management LLC increased its holdings in Mesoblast by 3.9% during the 4th quarter. Penbrook Management LLC now owns 232,100 shares of the companys stock worth $1,711,000 after purchasing an additional 8,800 shares during the last quarter. Finally, Wilbanks Smith & Thomas Asset Management LLC increased its holdings in Mesoblast by 6.0% during the 4th quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 25,025 shares of the companys stock worth $184,000 after purchasing an additional 1,425 shares during the last quarter. Institutional investors and hedge funds own 2.07% of the companys stock.

Mesoblast (NASDAQ:MESO) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.03). The firm had revenue of $2.21 million during the quarter, compared to analyst estimates of $6.54 million. Mesoblast had a negative net margin of 337.18% and a negative return on equity of 15.48%. On average, equities research analysts expect that Mesoblast will post -0.55 EPS for the current fiscal year.

About Mesoblast

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.

Read More: No Load Funds

Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.

Continue reading here:
Mesoblast limited (NASDAQ:MESO) Given Consensus Rating of Buy by Brokerages - Redmond Register

Stem Cell And Regenerative Therapy Market 2019-2024 Chain Analysis, Upstream Raw Materials Sourcing and Downstream Buyers – Feed Road

The global stem cell and regenerative medicines market should grow from $21.8 billion in 2019 to reach $55.0 billion by 2024 at a compound annual growth rate (CAGR) of 20.4% for the period of 2019-2024.

Report Scope:

The scope of this report is broad and covers various type of product available in the stem cell and regenerative medicines market and potential application sectors across various industries. The current report offers a detailed analysis of the stem cell and regenerative medicines market.

Request For Report Sample:https://www.trendsmarketresearch.com/report/sample/11723

The report highlights the current and future market potential of stem cell and regenerative medicines and provides a detailed analysis of the competitive environment, recent development, merger and acquisition, drivers, restraints, and technology background in the market. The report also covers market projections through 2024.

The report details market shares of stem cell and regenerative medicines based on products, application, and geography. Based on product the market is segmented into therapeutic products, cell banking, tools and reagents. The therapeutics products segments include cell therapy, tissue engineering and gene therapy. By application, the market is segmented into oncology, cardiovascular disorders, dermatology, orthopedic applications, central nervous system disorders, diabetes, others

The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The report presents detailed analyses of major countries such as the U.S., Canada, Mexico, Germany, the U.K. France, Japan, China and India. For market estimates, data is provided for 2018 as the base year, with forecasts for 2019 through 2024. Estimated values are based on product manufacturers total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

Report Includes:

28 data tables An overview of global markets for stem cell and regenerative medicines Analyses of global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024 Details of historic background and description of embryonic and adult stem cells Information on stem cell banking and stem cell research A look at the growing research & development activities in regenerative medicine Coverage of ethical issues in stem cell research & regulatory constraints on biopharmaceuticals Comprehensive company profiles of key players in the market, including Aldagen Inc., Caladrius Biosciences Inc., Daiichi Sankyo Co. Ltd., Gamida Cell Ltd. and Novartis AG

Summary

The global market for stem cell and regenerative medicines was valued at REDACTED billion in 2018. The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED to reach approximately REDACTED billion by 2024. Growth of the global market is attributed to the factors such as growingprevalence of cancer, technological advancement in product, growing adoption of novel therapeuticssuch as cell therapy, gene therapy in treatment of chronic diseases and increasing investment fromprivate players in cell-based therapies.

To Get Discount:https://www.trendsmarketresearch.com/report/discount/11723

In the global market, North America held the highest market share in 2018. The Asia-Pacific region is anticipated to grow at the highest CAGR during the forecast period. The growing government funding for regenerative medicines in research institutes along with the growing number of clinical trials based on cell-based therapy and investment in R&D activities is expected to supplement the growth of the stem cell and regenerative market in Asia-Pacific region during the forecast period.

Reasons for Doing This Study

Global stem cell and regenerative medicines market comprises of various products for novel therapeutics that are adopted across various applications. New advancement and product launches have influenced the stem cell and regenerative medicines market and it is expected to grow in the near future. The biopharmaceutical companies are investing significantly in cell-based therapeutics. The government organizations are funding research and development activities related to stem cell research. These factors are impacting the stem cell and regenerative medicines market positively and augmenting the demand of stem cell and regenerative therapy among different application segments. The market is impacted through adoption of stem cell therapy. The key players in the market are investing in development of innovative products. The stem cell therapy market is likely to grow during the forecast period owing to growing investment from private companies, increasing in regulatory approval of stem cell-based therapeutics for treatment of chronic diseases and growth in commercial applications of regenerative medicine.

Products based on stem cells do not yet form an established market, but unlike some other potential applications of bioscience, stem cell technology has already produced many significant products in important therapeutic areas. The potential scope of the stem cell market is now becoming clear, and it is appropriate to review the technology, see its current practical applications, evaluate the participating companies and look to its future.

The report provides the reader with a background on stem cell and regenerative therapy, analyzes the current factors influencing the market, provides decision-makers the tools that inform decisions about expansion and penetration in this market.

Make an Inquiry before [emailprotected]https://www.trendsmarketresearch.com/checkout/11723/Single

Read the original here:
Stem Cell And Regenerative Therapy Market 2019-2024 Chain Analysis, Upstream Raw Materials Sourcing and Downstream Buyers - Feed Road

Scientists Create Human ‘Body-On-A-Chip’ Featuring Tiny Replica Organs In The Lab – IFLScience

Researchers have created what they say is the world's most sophisticated lab model of the human body: a system of mini-organs made fromreal human cells and stem cells.

While it may sound like attempts to make a miniature Frankensteins monster in a petri dish, the researchers are actually hoping to create an entire lab model of miniaturized human organs that could become invaluable for drug testing and biomedical research.

Reporting in the journal Biofabrication, scientists from Wake Forest Institute for Regenerative Medicine (WFIRM) in North Carolina created a human organ tissue system that features a miniature heart-like organ that beats about 60 times a minute, a lung that breathes the air from the surrounding environment, and a liver that breaks down toxic compounds, as well as testicles and a colon.

Although just one-millionth the size of a full-sized adult human organ, these body-on-a-chip" systems are remarkably detailed, complete with their own blood vessel cells, immune system cells, and connective tissue cells. It also contains a microfluidic circuit thats able to circulate a drug throughout the system between organs, just like how a cardiovascular system pumps molecules through the human body in the blood.

Creating microscopic human organs for drug testing was a logical extension of the work we have accomplished in building human-scale organs, said study co-author Thomas Shupe of WFIRM in astatement. Many of the same technologies we have developed at the human-scale level, like including a very natural environment for the cells to live in, also produced excellent results when brought down to the microscopic level.

Don't worry, this isn't scientists creating a tiny "artificial human" the system is barely more thana load of blobs in a petri dish, not a conscious organism.

Organoids are invaluable tools for scientists looking to understand the human body. In one of the most incredible breakthroughs, researchers recently observed brain organoids that began to show signs of brain waves similar to those of preterm infants. Its hoped this kind of research could be used to understand how brain cells develop into the intensely complex organ currently sitting in your head.

They are also extremely useful for testing new pharmaceutical drugs because they react, in theory, just as a real human organ would. Plus, they are safe and relatively low-cost. The newly developed miniature organ model has already been used for a number of tests to assessthetoxicity of some drugs. In some instances, the organ model managed to show adrug might be dangerous or have some undesired effect, thereby potentially preventing harm to humans.

Link:
Scientists Create Human 'Body-On-A-Chip' Featuring Tiny Replica Organs In The Lab - IFLScience